NRXP Similar Chart Price Prediction
The price of NRXP is predicted to go up -6.66%, based on the high correlation periods with XPEL. The similarity of these two price pattern on the periods is 94.84%.
NRXP
XPEL
Down: -6.66%Similarity: 94.84%
NRXP Revenue Forecast
NRXP EPS Forecast
NRXP FAQs
What is bull’s view on NRXP?
What is bear's view on NRXP?
What is NRXP revenue forecast for next quarter？
What is NRXP eps forecast for next quarter？
NRXP Analyst's Forecast
Jason Kolbert
EF Hutton
Strong Buy
2024-10-21
Price Target
$31
Downside
0%
EF Hutton initiated coverage of NRx Pharmaceuticals with a Buy rating and $31 price target. NRx has "a vision to address the national crisis around suicide and PTSD" and is working to introduce the first NMDA-targeted drugs, engineered to eliminate the typical side effects of hallucinations, neurotoxicity, and akathisia, all of which limit efficacy. NRX-101 has shown its potential to act rapidly in reducing Acute Suicidal Ideation and Behavior, or ASIB, notes the analyst, who adds that the drug has the potential to expand to bipolar depression and PTSD-suicide. NRX is also seeking approval for NRX-100, an optimized and tamper-resistant formulation of ketamine, with a label and insurance, the analyst added.
